Single-agent paclitaxel did not show equivalence to doxorubicin and cyclophosphamide as adjuvant therapy for breast cancer in women with zero to three axillary nodes, found data presented at ASCO 2013.
Among patients with newly-diagnosed glioblastoma, adding bevacizumab to standard first-line chemoradiotherapy does not improve survival, found data presented at ASCO 2013.
Axillary radiotherapy offers 5-year survival rates comparable to surgical dissection of the axillary lymph nodes, and a lower risk of lymphedema, according to research presented at ASCO 2013.
Bevacizumab extended survival in women with relapsed/advanced cervical cancer, the first time a targeted agent has significantly improved OS in gynecologic cancer, according to data presented at ASCO 2013.
Sorafenib represents a potential new treatment option for patients with locally advanced or metastatic RAI-refractory differentiated thyroid cancer, according to research presented at ASCO 2013.
Older African-American women with breast cancer are nearly 1.5 times more likely to have poor physical performance compared with non-Hispanic whites, found research presented at ASCO 2013.
Postsurgical surveillance alone allows patients with early-stage seminoma to forego unnecessary additional therapy without reducing cancer-specific survival, found data presented at ASCO 2013.
Ipilimumab and nivolumab have greater clinical activity when administered concurrently than either agent alone in patients with advanced melanoma, according to a study presented at ASCO 2013.
Cardiovascular fitness in middle-aged and older men is a strong independent predictor of incident lung and colorectal cancer, according to data presented at ASCO 2013.
When less expensive options are available, patients with cancer, oncologists, and the general public are in favor of saving money by using less costly treatments, found research presented at ASCO 2013.
Please login or register first to view this content.
